Inventor
VELCHETI VAMSIDHAR
US16 patents
Patents
16 patentsUS10492723B2Dec 3, 2019
Predicting immunotherapy response in non-small cell lung cancer patients with quantitative vessel tortuosity
UNIV CASE WESTERN RESERVE21 citations93
US10049770B2Aug 14, 2018
Prediction of recurrence of non-small cell lung cancer
UNIV CASE WESTERN RESERVE34 citations93
US10078895B2Sep 18, 2018
Prediction of recurrence of non-small cell lung cancer with tumor infiltrating lymphocyte (TIL) graphs
UNIV CASE WESTERN RESERVE37 citations90
US10956795B2Mar 23, 2021
Predicting recurrence in early stage non-small cell lung cancer (NSCLC) using spatial arrangement of clusters of tumor infiltrating lymphocytes and cancer nuclei
UNIV CASE WESTERN RESERVE4 citations72
US10846367B2Nov 24, 2020
Predicting recurrence in early stage non-small cell lung cancer (NSCLC) with integrated radiomic and pathomic features
UNIV CASE WESTERN RESERVE6 citations71
US10950351B2Mar 16, 2021
Methods and apparatus for predicting benefit from immunotherapy using tumoral and peritumoral radiomic features
UNIV CASE WESTERN RESERVE6 citations70
US10902256B2Jan 26, 2021
Predicting response to immunotherapy using computer extracted features relating to spatial arrangement of tumor infiltrating lymphocytes in non-small cell lung cancer
UNIV CASE WESTERN RESERVE2 citations70
US10575774B2Mar 3, 2020
Predicting immunotherapy response in non-small cell lung cancer with serial radiomics
UNIV CASE WESTERN RESERVE2 citations69
US10441225B2Oct 15, 2019
Predicting disease recurrence following trimodality therapy in non-small cell lung cancer using computed tomography derived radiomic features and clinico-pathologic features
UNIV CASE WESTERN RESERVE2 citations68
US11350901B2Jun 7, 2022
Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomography
UNIV CASE WESTERN RESERVE1 citations60
US11574404B2Feb 7, 2023
Predicting recurrence and overall survival using radiomic features correlated with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC)
UNIV CASE WESTERN RESERVE1 citations59
US10441215B2Oct 15, 2019
Predicting immunotherapy response in non-small cell lung cancer with serial quantitative vessel tortuosity
UNIV CASE WESTERN RESERVE1 citations58
US11055844B2Jul 6, 2021
Predicting response to immunotherapy using computer extracted features of cancer nuclei from hematoxylin and eosin (HandE) stained images of non-small cell lung cancer (NSCLC)
UNIV CASE WESTERN RESERVE0 citations49
US10839513B2Nov 17, 2020
Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic features
UNIV CASE WESTERN RESERVE0 citations39
US10458895B2Oct 29, 2019
Predicting response to pemetrexed chemotherapy in non-small cell lung cancer (NSCLC) with baseline computed tomography (CT) shape and texture features
UNIV CASE WESTERN RESERVE0 citations36
US10346975B2Jul 9, 2019
Computerized analysis of computed tomography (CT) imagery to quantify tumor infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC)
UNIV CASE WESTERN RESERVE0 citations36